Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

References

• Badowski M, Pérez SE, Silva D, Lee A. Two's a company, three's a crowd: a review of initiating or switching to a two-drug antiretroviral regimen in treatment-naïve and treatment-experienced patients living with HIV-1. Infect Dis Ther. 2020;9(2):185–208.
   Web of Science ®Google Scholar
• Rossetti B, Montagnani F, De Luca A. Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother. 2018;19(7):713–738.
   PubMed Web of Science ®Google Scholar
• Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–155.
   PubMed Web of Science ®Google Scholar
• Borghetti A, Baldin G, Lombardi F, et al. Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med. 2018;23(7):452–454.
   Google Scholar
• Baldin G, Ciccullo A, Borghetti A, Di Giambenedetto S. Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019;74(5):1461–1463.
   PubMed Web of Science ®Google Scholar
• Lombardi F, Belmonti S, Borghetti A, et al. Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study. J Antimicrob Chemother. 2020;75(6):1599–1603.
   Web of Science ®Google Scholar
• Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: Results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019;74(3):739–745.
   PubMed Web of Science ®Google Scholar
• Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis. 2018;66(11):1794–1797.
   PubMed Web of Science ®Google Scholar
• van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71(8):1920–1929.
   PubMed Web of Science ®Google Scholar
• Cento V, Perno CF. Dolutegravir plus lamivudine two-drug regimen: safety, efficacy and diagnostic considerations for its use in real-life clinical practice-a refined approach in the COVID-19 era. Diagnostics. 2021;11(5):809.
   Web of Science ®Google Scholar
• Fabbiani M, Rossetti B, Ciccullo A, et al. Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: data from real-life ODOACRE cohort. HIV Med. 2021;22(9)Jul:843–853. Epub ahead of print. PMID: 34318591.
   PubMed Web of Science ®Google Scholar
• Neuhaus J, Jacobs DR, Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788–1795.
   PubMed Web of Science ®Google Scholar
• Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29(4):463–471.
   PubMed Web of Science ®Google Scholar
• Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep. 2012;9(2):139–147.
   PubMed Web of Science ®Google Scholar
• Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248–1259.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203(11):1637–1646.
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Bebu I, Tracy R, et al. D-dimer levels before HIV seroconversion remain elevated even after viral suppression and are associated with an increased risk of non-AIDS events. PLoS One. 2016;11(4):e0152588.
   PubMed Web of Science ®Google Scholar
• Tincati C, Mondatore D, Bai F, d'Arminio Monforte A, Marchetti G. Do combination antiretroviral therapy regimens for HIV infection feature diverse T-cell phenotypes and inflammatory profiles? Open Forum Infect Dis. 2020;7(9):ofaa340.
   Web of Science ®Google Scholar
• Aldo P, Marusov G, Svancara D, David J, Mor G. Simple Plex(™): a novel multi-analyte, automated microfluidic immunoassay platform for the detection of human and mouse cytokines and chemokines. Am J Reprod Immunol. 2016;75(6):678–693.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Brites CA Cheng CY Osiyemi O, Galera C, et al. Switching to the 2-drug regimen of dolutegravir/lamivudine (dtg/3tc) fixed-dose combination is non-inferior to continuing a 3-drug regimen through 48 weeks in a randomized clinical trial (salsa). In: 11th International AIDS Society Conference on HIV Science (IAS2021); July 18–21, 2021, Berlin, Germany, (OALB030).
   Google Scholar
• van Wyk J, Ait-Khaled M, Santos J, et al. Metabolic health outcomes at week 144 in the TANGO study, comparing a switch to DTG/3TC versus maintenance of TAF-based regimen. In: 11th International AIDS Society Conference on HIV Science (IAS2021); July 18–21, 2021, Berlin, Germany, (OPEB164).
   Google Scholar
• Serrano-Villar S, López-Huertas MR, Jiménez D, et al. Effects of switch from 3dr to 2dr on inflammatory biomarkers. In: Conference on Retroviruses and Opportunistic Infectious, March 6–11, 2021 | Virtual (Abstract n 527.)
   Google Scholar
• Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1and SWORD-2 studies. Lancet HIV. 2019;6:576–587.
   PubMed Web of Science ®Google Scholar
• María Llibre J, Cortés L, Aylott LF, et al. Inflammatory and atherogenesis markers 148 weeks postswitch to dtg + rpv in sword-1/-2. In: Conference on Retroviruses and Opportunistic Infectious, March 6–11, 2021 | Virtual (Abstract n 489).
   Google Scholar
• Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev. 2013;26(1):2–18.
   PubMed Web of Science ®Google Scholar
• Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep. 2017;14(3):93–100.
   PubMed Web of Science ®Google Scholar
• Martínez E, D’Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012;26(18):2315–2326.
   PubMed Web of Science ®Google Scholar
• Lake JE, McComsey GA, Hulgan T, et al. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial. HIV Med. 2014;15(7):431–441.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Baldin G, Capetti A, et al. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. Antivir Ther. 2019;24(1):63–67.
   PubMed Web of Science ®Google Scholar
• Mussini C, Lorenzini P, Cozzi-Lepri A, et al. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Med. 2018;16(1):79.
   Google Scholar